Biohaven Ltd.
NYSE:BHVNBiotechnology
Healthcare
$13.65 -1.62%
-$0.22 today
- Market cap
- $2.06B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
52W Low $7.48High $18.57
Volume 3.26M
Average 2.47M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$609.44M
FY 2025 · Annual
Investing Cash Flow
$300.56M
FY 2025 · Annual
Financing Cash Flow
$439.12M
FY 2025 · Annual
-35.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 65.64M | 193.56M | 28.79M | 71.96M | 112.36M |
| Change in Working Capital | 1.66M | (28.6M) | 24.61M | 16.81M | 1.36M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.03M | 5.93M | 4.87M | 710K | (6.39M) |
| Other Working Capital | 639K | (34.53M) | 19.74M | 16.1M | 7.74M |
| Other Non-Cash Items | (740K) | 106.25M | 16.13M | 167.34M | 5.74M |
| Operating Cash Flow | (145.84M) | (297.69M) | (331.73M) | (582.45M) | (609.44M) |
| Capital Expenditures | (938K) | (41.07M) | (3.05M) | (4.05M) | (715K) |
| Acquisitions (Net) | 1.88M | 0 | 0 | 391K | 0 |
| Purchases of Investments | 0 | (263.72M) | (194.12M) | (745.68M) | (266.88M) |
| Sales of Investments | 0 | 0 | 327M | 504.36M | 570M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1.85M) |
| Investing Cash Flow | 944K | (304.79M) | 129.83M | (244.97M) | 300.56M |
| Debt Repayment | 0 | 449.13M | 0 | 0 | 250M |
| Common Stock Issued | 0 | 283.8M | 243.23M | 675.52M | 189.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 138.45M | 34.66M | (31.32M) | 2.26M | (194K) |
| Financing Cash Flow | 138.45M | 767.6M | 211.91M | 677.77M | 439.12M |
| Effect of Forex Changes | 0 | 429K | (497K) | 75K | (3K) |
| Net Change in Cash | (6.45M) | 165.55M | 9.52M | (149.58M) | 130.24M |
| Free Cash Flow | (146.78M) | (338.76M) | (334.77M) | (586.5M) | (610.15M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$738.8M
+ D&A$9.9M
+ Stock-Based Comp$112.4M
+ Deferred Tax$0
+ Working Capital$1.4M
+ Other Non-Cash$5.7M
= Operating Cash Flow-$609.4M
- Capex-$715.0K
= Free Cash Flow-$610.2M
Analysis
FY2025 free cash flow is -$610.2M. FCF conversion is 82.6% of net income. Operating cash flow was -$609.4M, with capex of -$715.0K. The largest bridge item is Stock-Based Comp at $112.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
Does BHVN generate free cash flow?
Biohaven Ltd. (BHVN) generated -$610.15M of free cash flow in fiscal 2025.
How much operating cash flow does BHVN produce?
Operating cash flow was -$609.44M, before capital expenditures of $715,000.00.
Continue the stock analysis
Jump to another research area for this company.